Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | Access limitations: the key challenges facing RCC treatment in France

Laurence Albiges, MD, PhD, of the Gustave Roussy Institute, Villejuif, France, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA. She describes the key challenges facing French oncologists who specialize in the treatment of renal cell carcinoma. Whilst novel treatments are proving effective, access can be an issue.

Transcript (edited for clarity)

So we in France are facing, of course like in any country, the question of rapidly evolving treatment strategy in RCC. In metastatic RCC, the standard of care in second-line is nivolumab or

So we in France are facing, of course like in any country, the question of rapidly evolving treatment strategy in RCC. In metastatic RCC, the standard of care in second-line is nivolumab or cabozantinib for which we have access to. And right now, the limitation is in first-line. We are eagerly waiting for having access to a new combination and namely nivolumab plus ipilimumab based on the CheckMate 214 data that demonstrated overall survival benefit over sunitinib. And of course, the question on access to new strategy of TKI plus I-O, such as axitinib plus pembrolizumab, is of interest to the entire community in a old sub-group of patients with metastatic RCC.

So, in France we are keen on having access to these new strategies that had demonstrated overall survival when compared to standard care. We are keen on better defining the optimal sequence within patients. And so we are very happy to have some strategy trial such as BIONIKK trial, which tried to look at the gene expression profiling to better select patients in first-line towards TKI-based strategy or I-O-based strategy.

Read more...